1. Stauning, MA, Altintas, I, Kallemose, T, et al. Soluble urokinase plasminogen activator receptor as a decision marker for early discharge of patients with COVID-19 symptoms in the emergency department. J Emerg Med. Published online 26 March 2021. doi:10.1016/j.jemermed.2021.03.012
Google Scholar | Crossref2. Rasmussen, LJH, Ladelund, S, Haupt, TH, et al. Soluble urokinase plasminogen activator receptor (suPAR) in acute care: a strong marker of disease presence and severity, readmission and mortality. A retrospective cohort study. Emerg Med J. 2016;33:769-775.
Google Scholar | Crossref | Medline3. Rasmussen, LJH, Ladelund, S, Haupt, TH, Ellekilde, GE, Eugen-Olsen, J, Andersen, O. Combining national early warning score with soluble urokinase plasminogen activator receptor (suPAR) improves risk prediction in acute medical patients: a registry-based cohort study*. Crit Care Med. 2018;46:1961-1968.
Google Scholar | Crossref | Medline4. Oliveira, I, Andersen, A, Furtado, A, et al. Assessment of simple risk markers for early mortality among HIV-infected patients in Guinea-Bissau: a cohort study. BMJ Open 2012;2:e001587.
Google Scholar | Crossref | Medline5. Berres, M-L, Schlosser, B, Berg, T, Trautwein, C, Wasmuth, HE. Soluble urokinase plasminogen activator receptor is associated with progressive liver fibrosis in hepatitis C infection. J Clin Gastroenterol. 2012;46:334-338.
Google Scholar | Crossref | Medline6. Yilmaz, G, Mentese, A, Kaya, S, Uzun, A, Karahan, SC, Koksal, I. The diagnostic and prognostic significance of soluble urokinase plasminogen activator receptor in Crimean-Congo hemorrhagic fever. J Clin Virol. 2011;50:209-211.
Google Scholar | Crossref | Medline | ISI7. Outinen, TK, Tervo, L, Mäkelä, S, et al. Plasma levels of soluble urokinase-type plasminogen activator receptor associate with the clinical severity of acute puumala hantavirus infection. PLoS One. 2013;8:e71335.
Google Scholar | Crossref | Medline8. Rovina, N, Akinosoglou, K, Eugen-Olsen, J, Hayek, S, Reiser, J, Giamarellos-Bourboulis, EJ. Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia. Crit Care 2020;24:187.
Google Scholar | Crossref | Medline9. Azam, TU, Shadid, HR, Blakely, P, et al. Soluble urokinase receptor (SuPAR) in COVID-19-related AKI. J Am Soc Nephrol. 2020;31:2725-2735.
Google Scholar | Crossref | Medline10. Çitlenbik, H, Ulusoy, E, Er, A, et al. Levels of soluble urokinase plasminogen activator receptor in pediatric lower respiratory tract infections. Pediatr Allergy Immunol Pulmonol. 2019;32:121-127.
Google Scholar | Crossref | Medline11. Gumus, A, Altintas, N, Cinarka, H, Kirbas, A, Haziroglu, M, Karatas, M, Sahin, U. Soluble urokinase-type plasminogen activator receptor is a novel biomarker predicting acute exacerbation in COPD. Int J Chron Obstruct Pulmon Dis. 2015;40:357-365.
Google Scholar12. Håkansson, KEJ, Ulrik, CS, Godtfredsen, NS, et al. High suPAR and low blood eosinophil count are risk factors for hospital readmission and mortality in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2020;15:733-743.
Google Scholar | Crossref | Medline13. Godtfredsen, NS, Jørgensen, DV, Marsaa, K, et al. Soluble urokinase plasminogen activator receptor predicts mortality in exacerbated COPD. Respir Res. 2018;19:97.
Google Scholar | Crossref | Medline14. Chen, D, Wu, X, Yang, J, Yu, L. Serum plasminogen activator urokinase receptor predicts elevated risk of acute respiratory distress syndrome in patients with sepsis and is positively associated with disease severity, inflammation and mortality. Exp Ther Med. 2019;18:2984-2992.
Google Scholar | Medline15. Velissaris, D, Dimopoulos, G, Parissis, J, et al. Prognostic role of soluble urokinase plasminogen activator receptor at the emergency department: a position paper by the Hellenic sepsis study group. Infect Dis Ther. 2020;9:407-416.
Google Scholar | Crossref | Medline16. Schultz, M, Rasmussen, LJ, Høi-Hansen, T, et al. Early discharge from the emergency department based on soluble urokinase plasminogen activator receptor (suPAR) levels: a TRIAGE III substudy. Dis Markers. 2019;2019:3403549.
Google Scholar | Crossref | Medline17. Hayek, SS, Leaf, DE, Samman Tahhan, A, et al. Soluble urokinase receptor and acute kidney injury. N Engl J Med. 2020;382:416-426.
Google Scholar | Crossref | Medline18. Iversen, E, Houlind, MB, Eugen-Olsen, J. Soluble urokinase receptor and acute kidney injury. N Engl J Med. 2020;382:2166-2168.
Google Scholar | Crossref | Medline19. Kyriazopoulou, E, Panagopoulos, P, Metallidis, S, et al. An open label trial of anakinra to prevent respiratory failure in COVID-19. Elife. 2021;10:e66125.
Google Scholar | Crossref | Medline20. Bachelet, VC . Do we know the diagnostic properties of the tests used in COVID-19? A rapid review of recently published literature. Medwave. 2020;20:e7891-e7891.
Google Scholar | Crossref